Credit Suisse Ag Rhythm Pharmaceuticals, Inc. Call Options Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RYTM
# of Institutions
176Shares Held
62.4MCall Options Held
880KPut Options Held
84.1K-
Primecap Management CO Pasadena, CA7.75MShares$328 Million0.25% of portfolio
-
Black Rock Inc. New York, NY6.53MShares$276 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.4MShares$271 Million3.51% of portfolio
-
Goldman Sachs Group Inc New York, NY5.11MShares$216 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.3MShares$140 Million0.0% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $2.36B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...